Clinical Research

RG1123168

Biocept CNSide (FORESEE): A Longitudinal Therapy Response Monitoring Study with Leptomeningeal Metastases Using CNSide (CSF Tumor Cells) Compared to Standard of Care (CSF Cytology, Clinical Evaluation, and Imaging)

Investigators: Jonathan Yang, MD, PhD

RG1123131

DebioPharm: A Phase 1/2 open-label study of Debio 0123 in combination with temozolomide in adult participants with recurrent or progressive glioblastoma and of Debio 0123 in combination with temozolomide and radiotherapy in adult participants with newly diagnosed glioblastoma

Investigators: Jonathan Yang, MD, PhD

CSF BioBanking

Biorepository for Biomarker Development for Brain Tumors

Investigators: Jonathan Yang, MD, PhD

RG9517011/CC9961

A Phase II Randomized Trial of Proton vs. Photon Therapy – NRG-BN005

Investigators: Yolanda Tseng, MD

RG1007851/SWOG1706

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

Investigators: Janice Kim, MD

RG3116001/CC9701/RG1121754/CC10770

RADCOMP: pragmatic randomized trial of proton vs. photon therapy for patients with stage II or III breast cancer / RADCOMP ANCILLARY

Investigators: Waylene Wang, MD

RG1122627/GI-003

A Phase III Randomized Trial of Protons versus Photons for Hepatocellular Carcinoma

Investigators: Smith “Jim” Apisarnthanarax, MD

RG1121888/CC10825

GRECO-2: A Randomized, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer

Investigators: Smith “Jim” Apisarnthanarax, MD

RG3116003/CC9646

Functional liver imaging with sulfur colloid SPECT/CT in primary and metastatic liver cancer patients receiving liver-directed treatment: a pilot study

Investigators: Smith “Jim” Apisarnthanarax, MD

RG1121714

DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.

RG1005409/S1806

Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer.

RG1004762/S1802

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

RG1121495/STUDY00013118

Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE)

Investigators: Jonathan Chen, MD, PhD

STUDY00014709

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer: A Prospective Registry Trial

Investigators: Jay Liao, MD

RG1122983

RAMPART: A Phase II, Multicenter, Single-Arm Clinical Trial of Definitive Radiotherapy and CeMiPlimAb-Rwlc ImmunoTherapy for Locally Advanced, Unresectable Cutaneous Squamous Cell Carcinoma

Investigators: Upendra Parvathaneni, MB, FRANCR

RG1123073/HN009

Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100Mg/M2 ) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (30Mg/M2) For Patients With Locoregionally Advanced Squamous Cell Carcinoma Of the Head and Neck (SCCHN)

RG9215020/RTOG 1216

Randomized Phase II/III Trial Of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, Or Cisplatin-Atezolizumab In Pathologic High-Risk Squamous Cell Cancer Of The Head And Neck

RG1121804/CC10819

A Double Blind, Placebo Controlled Dose Range Finding Study to Assess the Safety, Pharmacokinetics, and Efficacy of TEMPOL for the Reduction of Severe Mucositis in Head and Neck Cancer Patients Undergoing Combined Radio- and Chemotherapy

Investigators: Jay Liao, MD

RG1121732/CC10810

CASPIAN-RT Trial: Hypofractionated consolidative radiation therapy after Durvalumab (MEDI4736) plus platinum-based chemotherapy in extensive stage small cell lung cancer

Investigators: Jing Zeng, MD

RG1006225/CC10356

A Phase III, Randomized, Placebo-controlled, Double blind, Multi-center, International Study of Durvalumab Following SBRT for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC4/RTOG-3515)

Investigators: Jing Zeng, MD

RG1123039

A Phase I Study Assessing the Safety and Tolerability of Ascending Doses of AZD1390 in Combination with Stereotactic Body Radiation Therapy (SBRT) in Patients with Metastatic Solid Tumor Malignancies

Investigators: Jonathan Yang, MD, PhD

RG1123050

Kazia: A Phase I Study with Expansion Cohort of Concurrent GDC-0084 with Radiation Therapy for Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations

Investigators: Jonathan Yang, MD, PhD

STUDY0001371/STUDY00015909

Increasing Native Radiation Oncology Access: Disparities and Solutions (INROADS) – Provider Survey / INROADS – Patient Survey

Investigators: Lia Halasz, MD

RG1121405/CC10743

Radiation Oncology Peripheral Blood Banking Protocol to Examine Immunologic Changes After Radiation Therapy

Investigators: Jing Zeng, MD

RG1123045/STUDY00015570

Biodosimetry: Quantitation of radiation induced protein adducts using mass spectrometry

Investigators: Peter Goff, MD, PhD

RG1001231/CC9329

Pediatric proton consortium registry (PPCR): A MultiCenter Registry of Pediatric Patients Treated with Proton Radiation Therapy

Investigators: Ralph Ermoian, MD

RG1000933/CC7931

Evaluation Tracking Project: A Prospective Chart Review of Patients Treated with Radiation Therapy

Investigators: Jing Zeng, MD